Results 141 to 150 of about 3,831 (231)

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018–2022)

, 2023
Hélio S. Sader, Rodrigo E. Mendes, Leonard R Duncan, John H. Kimbrough, Cecília G Carvalhaes, Mariana Castanheira   +5 more
openalex   +1 more source

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections [PDF]

Infectious Diseases and Therapy, 2021
openaire   +2 more sources

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. [PDF]

Antimicrob Agents Chemother
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD.   +9 more
europepmc   +1 more source

Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients. [PDF]

J Antimicrob Chemother
Cojutti PG, Toschi A, Pasquini Z, Paolini S, Maffini E, Bonifazi F, Zinzani PL, Giannella M, Viale P, Pea F.   +9 more
europepmc   +1 more source

Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa

, 2020
Marco Iannaccone, Matteo Boattini, Gabriele Bianco, Rossana Cavallo, Cristina Costa   +4 more
openalex   +2 more sources

Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]

Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M, Mazzei, P, Bokesch, PM, Bradley, JS, Capriati, A, Fornari, C, Habboubi, N, Auriol, FK, Borella, E, Vallespir, BP, Magalhaes, P, Hoover, R, Piana, C, Arrieta, A, Pasqua, OD   +14 more
core  

Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study. [PDF]

J Antimicrob Chemother
Frallonardo L, Guido G, De Gennaro N, De Iaco G, Signorile F, Cibelli M, De Luca A, Ritacco AI, Stolfa S, Di Gennaro F, Saracino A.   +10 more
europepmc   +1 more source

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection [PDF]

, 2018
Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis, Susan C Bleasdale, Olexiy Sagan, V.P. Stus, José A. Vázquez, В. І. Зайцев, Mohamed Bidair, Erik Chorvat, Petru Octavian Drăgoescu, Elena Fedosiuk, Juan Pablo Horcajada, Claudia Murta, Y. V. Sarychev, Ventsislav Stoev, Elizabeth E. Morgan, Karen Fusaro, David C. Griffith, Olga Lomovskaya, Elizabeth Alexander, Jeffery S. Loutit, Michael N. Dudley, Evangelos J. Giamarellos‐Bourboulis   +23 more
openalex   +1 more source

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

, 2022
Naphat Satapoomin, Punyawee Dulyayangkul, Matthew B. Avison   +2 more
openalex   +2 more sources

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>. [PDF]

Antimicrob Agents Chemother
Lavoie T, Sierra T, Daffinee K, Pogue JM, Achour B, LaPlante K.   +5 more
europepmc   +1 more source